Сочетание полиморфизмов генов PAI-1 –675 5G>4G, FXIII: Val34Leu G>T и ITGA2: 807 С>T у женщин с бесплодием может рассматриваться как предиктор неудач вспомогательных репродуктивных технологий:

Introduction. The effectiveness of assisted reproductive technology programs remains consistently low and does not exceed 40% in the number of positive results of human chorionic gonadotropin and 23% in terms of the birth rate. New ways of increasing the treatment effectiveness with in vitro fertilization (IVF) and carrying the new pregnancy are actual. Aim: to identify risk groups of IVF unsuccessful outcomes in women with infertility by studying of hemostasis genes polymorphisms. Materials and methods. We examined 130 women planning fertility treatment using IVF and 49 women as a control group. In all women we studied the most common hemostasis polymorphisms: FV: 1691 G > A, FII: 20210 G > A, FXIII: Val34Leu G > T, FGB: –455 G > A, ITGA2: 807 С > T, ITGB3: 1565 T > C, PAI-1 –675 5G > 4G by polymerase chain reaction, and compared their prevalence with similar pa- rameters of the control group. We analyzed the frequency of occurrence and significance of studied polymorphisms in 140 pro- tocols with embryo transfer in dependence to outcome. Results. In women with infertility planning IVF program, there were no significant differences in the prevalence rate of studied hemostasis polymorphisms in comparison with the control group. We revealed significantly high frequency of 3 polymorphisms occurrence — PAI-1 –675 4G/4G, ITGA2: 807 C > T and FХIII: Val34Leu G > T in women with negative outcomes of IVF program in com- parison with positive outcomes. Conclusion. Identification of risk groups of IVF failure based on the results of genetic testing of hemostasis polymorphisms is promising. REFERENCES: 1. Grandone E., Villani M., Dentali F. et al. Low-molecular-weight- heparin in pregnancies after ART. A retrospective study. Thromb Res. 2014;134(2):336–9. DOI: 10.1016/j.thromres.2014.06.004. 2. Momot A.P., Molchanova I.V., Tsyvkina L.P. Hemostasis changes in IVF cycle and their influence on the procedure effectiveness. [Izmeneniya sistemy gemostaza v cikle EKO i ih vliyanie na effek- tivnost’ procedury]. Byulleten’ medicinskoj nauki. 2017;4(8):77– 81 (in Russ.). 3. Fluhr H., Spratte J., Ehrhardt J. et al. Heparin and low-molecular- weight-heparins modulate the decidualization of human endome- trial stromal cells. Fertil Steril. 2010;93(8):2581–7. 4. Gamyrkina D.R., Vorobyova N.A. Role of genetic polymorphisms causing hypercoagulation in problem of habitual miscarriage. [Rol’ geneticheskih polimorfizmov, obuslavlivayushchih sostoyanie giperkoagulyacii, v probleme privychnogo nevynashivaniya bere- mennosti]. Tromboz, gemostaz i reologiya. 2016;(1):51–6 (in Russ.). 5. Putilova N.V., Tretyakova T.B., Pestryaeva L.A. et al. Inter- genic interaction in formation of hemostatic disorders at preg- nancy. [Mezhgennye vzaimodejstviya v formirovanii gemostazi- ologicheskih rasstrojstv pri beremennosti]. Tromboz, gemostaz i reologiya. 2015;(3):46–51 (in Russ.). 6. Malyshkina A.I., Fetisova I.N., Nazarova A.O. et al. Genes poly- morphism involved in regulation of blood vessels function at woman with threatened preterm delivery. [Polimorfizm genov, uchastvuyushchih v regulyacii funkcij sosudov, u zhenshchin s ugrozhayushchimi prezhdevremennymi rodami]. Tromboz, ge- mostaz i reologiya. 2017;(3):82–7 (in Russ.). DOI: 10.25555/ THR .2017.3.0799. 7. Momot A.P., Serduk G.V., Grigorieva E.E., Nikolayeva M.G. Ge- netically determined thrombophilias and noncarrying of preg- nancy. [Geneticheski obuslovlennye trombofilii i nevynashivanie beremennosti]. Tromboz, gemostaz i reologiya. 2012;(1):60–4 (in Russ.). 8. Kiseleva A.N., Butina E.V., Zaitseva G.A. et al. Role of genetic polymorphisms associated with thrombophilia, prothrombotic state and folate cycle disturbances at woman with reproductive disorders. [Rol’ geneticheskih polimorfizmov, associirovannyh s trombofiliej, protromboticheskimi sostoyaniyami i narusheni- yami folatnogo cikla, u zhenshchin s reproduktivnymi rasstrojst- vami]. Tromboz, gemostaz i reologiya. 2017;(2):52–7 (in Russ.). DOI: 10.25555/THR.2017.2.0784. 9. Safiullina S.I., Vuimo T.A., Ilizarova N.A. et al. A personalized approach to the correction of hemostatic sdisorders and throm- boprophylaxis in pregnant women with complicated obstetric anamnesis. [Personificirovannyj podhod k korrekcii narushenij sistemy gemostaza i tromboprofilaktike u beremennyh s oslozh- nennym akusherskim anamnezom]. Akusherstvo i ginekologiya. 2016;(12):58–65 (in Russ.). DOI: 10.18565/aig.2016.12.58–65. 10. Naheshletashvili I.V., Kalinina E.A., Kogan E.A. et al. Influence of hereditary and acquired thrombophilia on the outcome of pro- grams of assisted reproductive technologies. [Vliyanie nasled- stvennyh i priobretennyh trombofilij na iskhod programm vspomogatel’nyh reproduktivnyh tekhnologij]. Akusherstvo i ginekologiya. 2013;(3):29–34 (in Russ.). 11. GOST R53022.3–2008. Laboratory clinical technologies. Re- quirements for the quality of clinical laboratory research. Part 3. Rules for assessing the clinical information of laboratory tests. Na- tional standards of Russian Federation. [GOST R53022.3–2008. Tekhnologii laboratornye klinicheskie. Trebovaniya k kachestvu klinicheskih laboratornyh issledovanij. Chast’ 3. Pravila ocenki klinicheskoj informativnosti laboratornyh testov. Nacional’nye standarty Rossijskoj Federacii]. Moskva: Standartinform, 2009. 22 s (in Russ.). 12. Barut M.U., Bozkurt М., Kahraman М. et al. Thrombophilia and recurrent pregnancy loss: the enigma continues. Med Sci Monit. 2018;(24):4288–94. DOI: 10.12659/MSM.908832.